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Abstract 
Background: Enhancer of Zeste Drosophila Homologue 2 (EZH2) is a key regulator of transcription as a member of 
polycomb repressive complex 2 (PRC2) which exerts repression of downstream genes and is correlated to invasive-
ness and progression of different tumours. Therefore, we evaluated the expression of PRC2 proteins in pediatric soft 
tissue sarcoma (rhabdomyosarcoma, RMS and extraosseous Ewing sarcoma, EES) correlating them to the clinical 
outcome of the patients.
Methods: We analyzed PRC2 protein expression by quantitative real time PCR, western blotting and immunohisto-
chemistry in 17 soft tissue sarcomas (11 RMS and 6 EES) enrolled at Paediatric Oncology Units of the Second Univer-
sity of Naples. Expression analysis was performed for EZH2, SUZ12 and EED.
Results: Enhancer of Zeste Drosophila Homologue 2 was expressed with a different degree in 60 % of samples. 
Interestingly, the magnitude of EZH2 up regulation was significantly higher in patients presenting lymph node and/
or distant metastases at the diagnosis. Moreover, patients overexpressing EZH2 had a lower probability of survival 
compared to patients negative or with low EZH2 expression.
Conclusions: Our study suggests that high EZH2 expression is associated to increased aggressiveness of the disease. 
Therefore, drugs that control its activity could be potentially used in the epigenetic target treatment of tumors with 
these alterations.
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Background
The polycomb proteins retain the expression pattern of 
different cells by controlling chromatin structure during 
early development. In mammalians two polycomb group 
complexes are described, polycomb repressive complex 
1 (PRC1) and 2 (PRC2). PRC2 complex, conserved from 
Drosophila to mammals, consists of Enhancer of Zeste 
Drosophila Homologue 2 (EZH2), Suppressor of Zeste 
(SUZ12) and Embryonic Ectoderm Development (EED).
Polycomb repressive complex 2 catalyses the methyla-
tion of lysine 27 at histone H3, a repressive mark, and is 
involved in many biological processes as differentiation, 
cell identity, proliferation and stem-cell plasticity [1].
Whether a tumor derives from an embryonic stem cell/
multipotent progenitor or from the dedifferentiation 
of specialized cells, the initiation of malignant transfor-
mation can be also a result of epigenetic deregulation 
[2]. EZH2 is a histone methyltransferase that contains 
the SET domain with its active site. EZH2 overexpres-
sion was firstly linked to cancer by microarray analysis 
of prostate and breast cancer where it is associated to 
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aggressive, metastatic disease and to a poor clinical out-
come [3–7]. However, overexpression of EZH2 has also 
been described in other adult cancers including bladder, 
gastric, lung, and hepatocellular carcinoma [8].
Richter et  al. [9] found that EZH2 can be induced by 
FLI1/EWS due to its binding to EZH2 promoter in 
Ewing sarcoma (ES) in  vivo. In fact, about 85  % of ES 
are characterized by the specific translocation t(11;22)
(q24;q12) inducing the specific transcript of the fusion 
protein FLI1/EWS. The correlation between EZH2 
expression and growth control of ES was suggested by 
both ES growth inhibition in  vitro and delayed tumor 
development and metastases in mice induced by RNA 
interference-mediated inhibition of EZH2. Moreover, 
down-regulation of EZH2 reduced nerve growth factor 
receptor (NGFR) expression, which is an essential marker 
of neuroectodermal stem cells. Mutations of EZH2 were 
also described in ES even if correlations to patient prog-
nosis were not found [10]. In addition, epigenetic regu-
lation of polycomb target genes, in particular HOXD 
genes, is altered in ES [11].
Enhancer of Zeste Drosophila Homologue 2 overex-
pression was also found in soft tissue sarcoma as it is a 
key factor in the proliferation and survival of PAX3-
FOXO1 alveolar rhabdomyosarcoma (RMS) cells work-
ing, at least in part, by repressing FBXO32. In fact, the 
reduction of EZH2 activity represents a novel adjuvant 
strategy to eradicate high-risk PAX3-FOXO1 alveolar 
RMS [12].
It was also demonstrated that silencing of EZH2 pro-
motes the recruitment of a multiprotein complex at 
muscle-specific promoters in RMS cells and is directly 
involved in the induction of a muscular differentiation 
program in these cells [13]. Some studies exist also on 
adult sarcomas such as synovial sarcomas in which it was 
found that high EZH2 expression is predictive of devel-
oping distant metastases even in the better-differentiated 
subtypes [14].On the other hand, poor data are available 
on childhood soft tissue sarcomas.
Epigenetic silencing of tumor suppressor genes, includ-
ing EZH2, in cancer has evoked the use of potential ther-
apeutic strategies based upon inhibitors of epigenetic 
enzymes. One reported anti-EZH2 drug is deazaneplan-
ocin A (DZNep), an inhibitor of S-adenosyl-l-homo-
cysteine (SAH) hydrolase that promotes degradation of 
the PRC2 complex and indirectly inhibits EZH2 through 
effects on intracellular SAH concentrations; GSK126 is a 
small-molecule that directly inhibits both wild-type and 
mutant EZH2 methyltransferase activities [15, 16].
Some studies showed that SUZ12 has been subjected to 
chromosomal aberrations in endometrial stromal sarco-
mas (ESS). EES account for less than 10 % of uterine sar-
comas and the most frequent rearrangement is a t(7;17) 
translocation leading to the fusion of the JAZF1 and 
SUZ12 genes that map to chromosomes 7 and 17, respec-
tively [17, 18].
While SUZ12 and EED mutations have only been 
found to have loss-of-function effects, EZH2 mutations 
have been found to have both activating and inactivating 
functions in different cancers [19].
Deletions and inactivating mutations of SUZ12 and 
EED are found in malignant peripheral nerve sheath 
tumors (MPNSTs) [20].
SUZ12 inactivating mutations cause a decrease or loss 
of H3K27me3 and a reciprocal gain of H2K27 acetylation 
and H3K4me3, which enables active transcription factors 
to be recruited and the disease to progress [21]. SUZ12 is 
overexpressed in many human cancers, as ovarian cancer, 
mantle cell lymphoma or non-small cell lung cancer and 
breast cancer [22].
In the present manuscript, we have studied the expres-
sion of the polycomb complex proteins EZH2, SUZ12 
and EED in paediatric soft tissue sarcomas correlating 
the expression with the clinical outcome of the patients.
Methods
Patients and tumor samples
Tumor samples were collected from 17 patients affected 
by paediatric soft tissue sarcomas (11 RMS and 6 EE) 
treated at Paediatric Oncology Unit of Second University 
of Naples.
Tumors were classified according to the Intergroup 
RMS Studies (IRS) grouping: stage I, tumor macroscopi-
cally and microscopically removed; stage II, macroscopic 
complete resection but microscopic residuals; stage III, 
macroscopic complete resection but microscopic residu-
als and lymph nodes affected and not removed; and stage 
IV, metastasis present or non-regional lymph nodes 
involved. Normal controls (bone tissue and muscle) were 
formalin fixed and paraffin-embedded at our Pathology 
Unit. The study was approved by regional ethical review 
board at the Second University of Naples and performed 
in compliance with the Helsinki Declaration. All patients 
were aware and gave written informed consent.
RNA extraction and quantitative real‑time PCR
Total RNA was extracted from cell cultures using TRI 
REAGENT (Molecular Research Center Inc., OH, USA) 
according to the manufacturer’s protocol. RNA from 
paraffin-embedded tissues was extracted with RNeasy 
FFPE kit (Invitrogen). The reactions were run on an ABI 
PRISM®7900HT Sequence Detection System; the cycling 
conditions were 10  min at +95  °C (initial denaturation) 
followed by 40 cycles of 15 s at +94 °C (denaturation) and 
1  min at +68  °C (annealing/extension/data collection). 
Specific primers for human EZH2, SUZ12, and EED 
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were designed (Table 1). In the first step, we determined 
the stability of a control gene (Beta-actin) for the nor-
malization of the real-time PRC products. Assays were 
performed in triplicate. We used the 2−ΔΔCt method to 
analyse the obtained data.
Protein extraction and western blot analysis
Proteins were extracted using lysis-buffer with protease-
inhibitors. Protein concentration was quantified using 
Bradford assay (Bio-Rad). 30  μg of protein was run on 
polyacrylamide gel and blotted onto PVDF membrane 
(Millipore, Marlborough, MA). Immunoblotting was 
performed using primary antibodies against EZH2 (C-1), 
SUZ12 (D-10) and EED (H-300) (Santacruz Biotechnol-
ogy, INC) (1:500). Bands were visualized using a chemi-
luminescent system (ECL-Amersham). Quantity One 
1-D analysis software (Biorad Laboratories) was used to 
estimate the intensity of each band. Results were normal-
ized against the level of actin expression in each sample. 
It was obtained a range of arbitrary intensities of each 
bands from 0 to 190 %, with a median value of 70 %. We 
have selected intensity value higher than 70 % in order to 
quantify the expression of the proteins as high, instead 
different proteins lower or equal to 70 % were considered 
as low expression.
Immunohistochemistry
Tissue section of 4 mm-thick were deparaffinised, rehy-
drated and washed in PBS. Sections were quenched 
sequentially in 3  % H2O2 for 15  min and blocked with 
PBS-6  % not fat-dry milk (Biorad; Hercules, CA) for 
60  min at room temperature. EZH2 (ENX-1)-166,609 
primary antibody (SantaCruz Biotecnology, INC) was 
incubated at 1:100 dilution at 4 °C overnight. Secondary 
anti-mouse biotinylated antibody was incubated at 1:200 
at 4 °C for 60 min.
Automated autostainer (Dako Immunostainer) was 
utilized to visualize positive slides with avidin–biotin-
peroxidase method. The percentage of positive nuclei 
stained for EZH2 was quantified by scoring for semi-
quantitatively levels of expression. At least 5 fields per 
section by 2 blinded observers was considered; in rare 
cases of discrepancy, the sections were analyzed by an 
additional two independent observers. EZH2 was con-
sidered positive when nuclear staining was identified in 
at least 10 % of the neoplastic cells. On the other hand, 
normal lymphocytes were all immune negative for EZH2 
in same sections. A negative control was obtained by 
replacing the primary antibody with a normal murine 
IgG. EZH2-staining intensity was scored weak when 
recorded in at least 10 % cells and strong when recorded 
in more than 10 % cells. Each section was observed using 
an DM LB2 microscope (Leica St. Gallen, Switzerland) at 
400× magnification. Images were acquired through Digi-
tal Leica software with Leica Digital Camera DM LB2.
Statistical analysis
The Chi squared test was used for univariate analysis of 
PRC2 proteins and categories of different prognostic fac-
tors. The patients’ dichotomous variables were assessed 
according to their ability to influence overall survival 
(OS). Survival differences (OS), estimated at 5  years by 
the Kaplan–Meier analysis, were evaluated using a log-
rank test.
In the OS analysis, all deaths were considered treat-
ment failures. Results were expressed as probability (per-
cent) and 95 % confidence intervals (CI). Data are given 
as mean  ±  SD. Differences were assessed by t test and 
p < 0.05 were considered statistically significant.
Results
Main clinical and pathological characteristics of the 
patients
Seventeen paediatric patients (6 males and 11 females), 
affected by RMS or EES, were included in this study. The 
age of patients ranged from 3 to 160  months (median 
55  months, mean: 71.7  ±  55.4). According to the IRS 
grouping 1 patient with RMS was classified as stage 
II, seven as stage III and three as stage IV, respectively. 
Among the 6 patients with EES 1 was stage II, 4 stage III 
and 2 stage IV, respectively (Table 2). Overall, at a 5-year 
follow-up (median  =  60  months 95  % CI 18.3–60.0), 9 
patients (52.9 %) were alive and in continuous complete 
remission.
EZH2 was highly expressed in cancer cells of soft tissue 
sarcomas (RMS and EES)
Many studies showed that expression of EZH2, the cat-
alytic subunit of PRC2 complex, is frequently overex-
pressed in several adult tumors. In order to confirm these 
data in paediatric cancers, we analyzed gene and protein 
expression of PRC2 subunits.
The quantitative analysis of primary samples at diag-
nosis (11 RMS and 6 EES), based on RNA sample avail-
ability, showed an overexpression only of EZH2 but not 
of either EED or SUZ12 that showed expression levels 
Table 1 Primer sequences for quantitative real time-poly-
merase chain reaction
Gene Sense Antisense
EZH2 5′cgcttttctgtaggcgatgt 3′ 5′tgggtgttgcatgaaaagaa 3′
SUZ12 5′gggagactattcttgatgggaag3′ 5′actgcaacgtaggtccctga 3′
EED 5′gaaattccatccaagagatcca 3′ 5′tggatattccataatcgtaaagca3′
β-actin 5′gcgagaagatgacccagatc 3′ 5′ggatagcacagcctggatag 3′
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similar to control samples and normal counterparts. 
In details, the analysis showed 0.2 to 4.1-fold higher 
expression of EZH2, compared to the control samples, in 
either RMS or EES, respectively (p = 0.02 and p = 0.008, 
respectively).
On the other hand, SUZ12 and EED expression levels 
were 0.2 to 1-fold and 0.07 to 1-fold decreased, respec-
tively, if compared to normal controls (p > 0.05) (Fig. 1).
Moreover, we studied the protein expression of EZH2, 
SUZ12, and EED, by immunoblotting.
We have observed protein expression in 10 samples 
(58.8 %) for EZH2, 4 (23.5 %) for SUZ12, and 15 (88.2 %) 
for EED out of the 17 patients enrolled in the study, 
respectively. Western blotting analysis suggested a gen-
eral upregulation of EZH2 and totally confirmed the 
results obtained by qRT-PCR. We have also quantified 
proteins expression through the densities of the corre-
sponding bands after laser scanning and represented the 
results as percentage. EZH2 showed low levels of expres-
sion in 2 samples (20 %), and high levels in the remaining 
8 (80 %) out of the 10 samples analysed; the four SUZ12 
positive samples had high expression, while EED showed 
low expression in 1 sample (7 %) and high expression in 
14 (93  %) out of the 15 samples examined (Figs.  2, 3). 
When we compared EZH2, SUZ12 and EED expression 
with clinical and biological characteristics of patients, we 
did not find any significant correlation.
Immunohistochemical analysis was performed in pri-
mary tumors to quantify and localize the expression 
of EZH2 protein. Microscopy pictures showed nuclear 
localization of EZH2.
Strikingly, nuclear EZH2 protein staining was low in 
2/10 (Fig. 4a) and high (Fig. 4b) in 8/10 of analyzed posi-
tive samples. These findings confirmed that the expres-
sion of EZH2 protein is elevated in primary tumors. 
The data obtained with IHC had a good correlation with 
those obtained by western blotting (p < 0.05).
EZH2 mRNA high levels are correlated to metastatic 
disease
Heterogeneity of molecular expression within individual 
tumors and between the localized and metastatic tumors 
has been reported in some types of cancers [23–25].
We grouped the patients on the basis of EZH2 high or 
low expression and presence or absence of regional/dis-
tant lymph node and/or distant metastases. The patients 
with intratumour EZH2 high expression had stage III 
(positive lymph nodes and not removed) or stage IV at 
diagnosis (8/17). In fact, the fold-change average of EZH2 
in this group was 3.7, whereas in the other patients (9/17) 
was 2.2, close to the limit of 1.1-fold used for the detec-
tion of mRNA expression. The t test performed on the 
two groups with low and high EZH2 expression, sug-
gested that higher EZH2 mRNA levels were correlated 
to presence of lymph node and/or distant metastases (p 
value = 0.04) (Fig. 5a).
The Kaplan–Meier analysis of all patients, comparing 
OS curves after 5 year from diagnosis, demonstrates that 
the 10 patients EZH2-expressing had a lower probability 
of survival compared to the 7 cases negative for EZH2 
(15 vs 100 %) (log-rank test, p = 0.02, Fig. 5b). No signifi-
cant differences in OS rate were found between patients 
stratified according to SUZ12 and EED expression (log-
rank test p > 0.05) (Fig. 5 c and d).
Discussions
Cancer is considered a developmental disease and 
changes of biologic processes, that are central to normal 
embryonic development, are main features of human 
malignancy. Nowhere, this is more evident than in paedi-
atric tumors, where alterations of normal development are 
believed to be the origin of many childhood tumors. Over 
the past decade, to begin a new course for innovative anti-
cancer treatments, pre-clinical studies on the modulation 
of epigenetic regulators have been performed. Since epi-
genetic processes are key players in cell tissue specifica-
tion during the embryonal life, this approach seems to be 
particularly attractive for those cancers, such as pediatric 
cancer, in which the pathogenic mechanism implicates the 
deregulation of genes controlling the lineage commitment 
Table 2 Clinical and  biological data of  the 17 patients 
enrolled in the study
RMS rhabdomyosarcoma; EES extraosseous Ewing sarcoma; DOD dead of disease
Clinical characteristics Number of patients (%)
Gender







 RMS 11 (64.7)
 EES 6 (35.3)
Stage
 RMS and EES
  I 0
  II 2 (11.7)
  III 11 (64.7)
  IV 4 (23.5)
Outcome
 Alive 9 (52.9)
 DOD 8 (47)
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[2]. Many studies have shown that the overexpression of 
EZH2 in human cancers is often associated with poor 
prognosis [4, 12, 26]. Undifferentiated stem-like cancers 
express EZH2 that promotes cancer cell proliferation and 
metastasis formation by inhibiting several tumor suppres-
sor genes [27].The present work was aimed to evaluate 
expression of PRC2 subunits in 17 paediatric tumor sam-
ples and to correlate them to the prognosis of the tumour 
diseases. In this study, we report that EZH2 is aberrantly 
over-expressed in primary tumors if compared to normal 
tissues, thus indicating that the high levels of expression 
of EZH2 is a common molecular lesion of RMS and EES. 
Moreover, we show that its expression is significantly cor-
related to a lower probability of OS. Interestingly, t test 
performed on the two sub-groups with low or high EZH2 
expression, suggests that higher EZH2 mRNA levels are 
correlated to the presence of lymph node and/or distant 
metastases. The toleration and diffusion of genetic lesions 
that trigger malignant transformation depends upon epi-
genetic plasticity in the target cell. This model is longer 
supported in paediatric solid tumors that, at the contrary 
of adult malignancies, derive from relatively few genetic 
mutations progressing to invasive, drug-resistant and 
metastatic phenotypes in spite of the presence of rather 
stable genomes [2]. Dysregulation of EZH2 might confer 
acquired proliferative and migratory properties reverting 
cells that normally differentiate. Moreover, high expres-
sion levels of EZH2 detected in primary tumor tissue 
could be exploited to improve quality of tumor stage clas-
sification. Our results agreed with Richter and colleagues 
that found EZH2 responsible for the undifferentiated phe-
notype of EES by maintaining a stemness gene expression 
signature, inhibiting differentiation [9]. EWS/FLI1 has 
been found to induce the expression of EZH2 by direct 
Fig. 1 a EZH2, b SUZ12 and c EED expression evaluated through real time PCR between the control samples (CTRL) and soft tissue sarcoma sam-
ples
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binding to its promoter in ES cell lines. EZH2 expres-
sion and function were regulated by numerous different 
mechanisms, which could lead to the overexpression or 
increased activity of EZH2 in RMS. The involvement of 
the MYC transcription factor family, particularly MYCN, 
has been showed in RMS tumorigenesis. Interestingly 
MYC induces EZH2 expression by repression of micro-
RNA-26a [28]. Also, EZH2 expression is induced by E2F1 
and repressed by activated Rb, and its activity is stimu-
lated by CDK1/2.
The particular association of characteristic fusion genes 
with RMS and EES suggests that chimeric oncoproteins 
play a leading role in the development of these paediat-
ric sarcomas. In both entities, expression of aberrant 
fusion proteins affects important transcriptional regula-
tors and promotes cellular transformation by modulating 
the transcription of specific target genes [29]. Our results 
were in agree with Burdach and colleagues that demon-
strated loss of regulation of both EED and SUZ12 expres-
sion in Ewing tumors [30].
We hypothesize that the different expression 
between RNA and protein levels could depend on 
post-translational regulation for these two genes, by 
mutation in ubiquitin system or in its targets result-
ing in proteins stabilization; in a next study we will 
extend in a larger sample size the evaluation of mRNA 
and protein expression of these epigenetic regulat-
ing factors and we will analyze the mechanisms at the 
basis of the different expression of their mRNAs and 
proteins.
In conclusion, our data provide evidence that EZH2 
abnormal over-expression is involved in sustaining 
Fig. 2 PRC2 expression (EZH2, SUZ12 and EED) in RMS samples evaluated through immunoblotting (a) and representation of the densities of the 
bands expressed as percentage of expression after laser scanning (b)
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proliferation and inhibiting myogenic differentiation of 
paediatric soft tissue sarcomas. More importantly, our 
results indicate that pharmacological targeting of EZH2 
might represent a potentially valid approach to be used 
as treatment adjunctive to conventional therapy in order 
to make the latter more efficacious. Although there is an 
obvious rationale for inhibiting EZH2 function in malig-
nancies in which this gene is overactivated, the finding 
of inactivating mutations in myeloid neoplasms suggests 
that this approach will need to be employed with caution. 
Understanding how to effectively combine current treat-
ments with future histone demethylating agents will be a 
major challenge in the coming years.
Conclusions
Our study suggests that unfavourable outcome and 
tumor progression of paediatric soft tissue sarcoma 
is linked to abnormal over-expression of EZH2 and 
Fig. 3 PRC2 expression (EZH2, SUZ12, and EED) in EES samples evaluated through immunoblotting (a) and representation of the densities of the 
bands expressed as percentage of expression after laser scanning (b)
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Fig. 4 (a, b) Representative immunohistochemical staining showing EZH2 expression in sections of primary tumor tissue of RMS. Brown-orange 
color in nuclei indicates strong positive staining (400× Magnification). Normal control lymphocytes are negative. Red arrow: positive area; blue 
arrow: negative normal lymphocytes
Fig. 5 a EZH2 expression evaluated through real time PCR in metastatic and localized soft tissue samples. b All patients Kaplan–Meier analysis of 
overall survival (OS) stratified for EZH2, c SUZ12 and d EED expression
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malignancy grade is its effect. Novel therapeutic strate-
gies in the inhibition of carcinogenesis and progression 
of paediatric could be provided by EZH2 inhibition.
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